BATS:ARKG ARK Genomic Revolution ETF (ARKG) Price, Holdings, & News $22.40 -1.21 (-5.13%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$22.52 +0.12 (+0.52%) As of 04/25/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesHoldingsOwnershipRatingsBuy This Stock About ARK Genomic Revolution ETF (BATS:ARKG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARKG alerts:Sign Up Key Stats Today's Range$24.20▼$25.2450-Day Range$18.27▼$29.7952-Week Range$17.51▼$31.16Volume4.90 million shsAverage Volume2.76 million shsMarket Capitalization$1.02 billionAssets Under Management$961.56 millionDividend YieldN/ANet Expense Ratio0.75%Aggregate RatingModerate Buy ETF OverviewThe ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.Read More… ARK Genomic Revolution ETF ExpensesTypeARKGTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.75%0.57%0.56%0.57%0.53%Other Expenses0.00%0.57%0.49%0.45%0.52%Total Expense0.75%0.73%0.72%0.69%0.71%Fee Waiver0.00%-0.71%-0.49%-0.34%-0.54%Net Expense0.75%0.60%0.63%0.65%0.60% Receive ARKG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARK Genomic Revolution ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address ARKG ETF News HeadlinesBMO Announces the Termination of Certain BMO Mutual FundsApril 17, 2025 | finance.yahoo.comMarket sell-off shakes ETF issuers as Ark Invest gets hit the hardestMarch 18, 2025 | msn.comThe most powerful man in D.C.Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.April 28, 2025 | Porter & Company (Ad)908 Devices Makes Key Divestiture (Rating Upgrade)March 6, 2025 | seekingalpha.comHC Wainwright & Co. Initiates Coverage of Intellia Therapeutics (NTLA) with Buy RecommendationMarch 5, 2025 | msn.comARK Invest Europe Prepares to Close Rize Digital Payments ETFFebruary 20, 2025 | finance.yahoo.comSee More Headlines ARKG ETF - Frequently Asked Questions How have ARKG shares performed this year? ARK Genomic Revolution ETF's stock was trading at $23.5450 at the beginning of 2025. Since then, ARKG stock has decreased by 4.9% and is now trading at $22.3980. View the best growth stocks for 2025 here. Who are ARK Genomic Revolution ETF's major shareholders? Top institutional investors of ARK Genomic Revolution ETF include IMC Chicago LLC, SG Americas Securities LLC (0.32%), Cambridge Investment Research Advisors Inc. (0.21%) and Ameritas Advisory Services LLC (0.09%). How do I buy shares of ARK Genomic Revolution ETF? Shares of ARKG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARK Genomic Revolution ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARK Genomic Revolution ETF investors own include Invesco QQQ (QQQ), ARK Innovation ETF (ARKK), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), AbbVie (ABBV) and PayPal (PYPL). Fund Details IssuerARK Fund NameARK Genomic Revolution ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:ARKG Inception Date10/31/2014 Fund ManagerCatherine Wood WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings34 Fund Statistics Assets Under Management$961.56 million Average Daily Volume$3.50 million Discount/Premium0.01% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorARK Investment Management LLC CustodianThe Bank of New York Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume2,474 Put Options248 Call Options2,226 Miscellaneous Outstanding Shares45,450,000Beta1.80 Creation Unit50,000 Creation Fee$500.00 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Top 10 ARKG HoldingsTwist Bioscience (NASDAQ:TWST)Holding Weight: 9.03%CRISPR Therapeutics (NASDAQ:CRSP)Holding Weight: 8.23%Recursion Pharmaceuticals (NASDAQ:RXRX)Holding Weight: 6.98%Tempus AI (NASDAQ:TEM)Holding Weight: 6.97%Guardant Health (NASDAQ:GH)Holding Weight: 6.53%Natera (NASDAQ:NTRA)Holding Weight: 6.27%Adaptive Biotechnologies (NASDAQ:ADPT)Holding Weight: 5.94%Schrödinger (NASDAQ:SDGR)Holding Weight: 5.92%CareDx (NASDAQ:CDNA)Holding Weight: 4.38%Veracyte (NASDAQ:VCYT)Holding Weight: 4.04%Full Holdings DetailsARKG Sector ExposureARKG Industry Exposure This page (BATS:ARKG) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share ARK Genomic Revolution ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
